CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project explores a new cancer vaccine strategy targeting prostate cancer by enhancing immune responses through a combination of viral vectors. It aims to improve the effectiveness of immunotherapy by evaluating the vaccine's impact on tumor burden and patient outcomes.
A successful vaccine against cancer is most likely to work through the induction of potent CD8+ T cells that can successfully kill tumour cells.
But achieving this has proved difficult and only low level responses are induced by current vaccine approaches.
Nonetheless, two therapeutic immunisation strategies have shown partial success in targeting prostate cancer, and one recently reached licensure.Recently, advances in infectious disease vaccinology have identified an exceptionally potent heter…
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, OXFORD
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Italy, SIENA
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Switzerland, LAUSANNE
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Italy, SIENA
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
